| James R Ostrander, DO | |
|
789 Minot Ave, Auburn, ME 04210-3924 | |
| (207) 795-8475 | |
| (207) 795-8490 |
| Full Name | James R Ostrander |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 23 Years |
| Location | 789 Minot Ave, Auburn, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841224466 | NPI | - | NPPES |
| 414730099 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 1837 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Maine Medical Center | Lewiston, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Maine Medical Center | 2567379563 | 347 |
News Archive
People with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do not have an early relapse, according to a new study published in the November 4, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology. The study is one of the first to examine how MS relapses affect people during different time periods of the disease.
SPO Medical Inc. (SPOM)s intellectual property (IP) portfolio to a total of eight patents. These latest patents, developed by the SPO Medical engineering team, increases the Company's technological competitive edge in providing innovative, high performance oximetry solutions for a variety of market applications.
Episona Inc., an epigenetics data company focused on improving outcomes in reproductive health, announced today the launch of Seed, an innovative new male fertility test, at the American Society for Reproductive Medicine Scientific Congress& Expo.
Garvan Institute scientists have discovered how a hormone, known as neuropeptide Y (NPY), can prevent our immune system functioning properly, paving the way for two new major opportunities for therapeutic intervention.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
› Verified 8 days ago
| Entity Name | Central Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689653487 PECOS PAC ID: 2567379563 Enrollment ID: O20040324000441 |
News Archive
People with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do not have an early relapse, according to a new study published in the November 4, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology. The study is one of the first to examine how MS relapses affect people during different time periods of the disease.
SPO Medical Inc. (SPOM)s intellectual property (IP) portfolio to a total of eight patents. These latest patents, developed by the SPO Medical engineering team, increases the Company's technological competitive edge in providing innovative, high performance oximetry solutions for a variety of market applications.
Episona Inc., an epigenetics data company focused on improving outcomes in reproductive health, announced today the launch of Seed, an innovative new male fertility test, at the American Society for Reproductive Medicine Scientific Congress& Expo.
Garvan Institute scientists have discovered how a hormone, known as neuropeptide Y (NPY), can prevent our immune system functioning properly, paving the way for two new major opportunities for therapeutic intervention.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James R Ostrander, DO 789 Minot Ave, Auburn, ME 04210-3924 Ph: (207) 795-8475 | James R Ostrander, DO 789 Minot Ave, Auburn, ME 04210-3924 Ph: (207) 795-8475 |
News Archive
People with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do not have an early relapse, according to a new study published in the November 4, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology. The study is one of the first to examine how MS relapses affect people during different time periods of the disease.
SPO Medical Inc. (SPOM)s intellectual property (IP) portfolio to a total of eight patents. These latest patents, developed by the SPO Medical engineering team, increases the Company's technological competitive edge in providing innovative, high performance oximetry solutions for a variety of market applications.
Episona Inc., an epigenetics data company focused on improving outcomes in reproductive health, announced today the launch of Seed, an innovative new male fertility test, at the American Society for Reproductive Medicine Scientific Congress& Expo.
Garvan Institute scientists have discovered how a hormone, known as neuropeptide Y (NPY), can prevent our immune system functioning properly, paving the way for two new major opportunities for therapeutic intervention.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
› Verified 8 days ago
John M Woytowicz, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Great Falls Plz Ste 21, Auburn, ME 04210 Phone: 207-330-3950 Fax: 207-330-3955 | |
Kurt Martin Oswald, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 117 Goff St, Suite 1, Auburn, ME 04210 Phone: 207-784-3000 Fax: 207-782-4821 | |
Paul James Balzer Jr., MD Family Medicine Medicare: Medicare Enrolled Practice Location: 15 Gracelawn Rd, Suite 103, Auburn, ME 04210 Phone: 207-330-3950 Fax: 207-330-3950 | |
Dr. Michael Rifkin, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 190 Stetson Rd, Auburn, ME 04210 Phone: 207-784-7388 Fax: 207-795-2043 | |
Dr. Joel A Kase, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 60 Second St, Auburn, ME 04210 Phone: 207-783-3333 Fax: 207-782-9723 | |
Amy L.r. Dudley, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Great Falls Plz Ste 21, Auburn, ME 04210 Phone: 207-330-3950 Fax: 207-330-3955 | |
Gerald Guy Lachance, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 789 Minot Ave, Auburn, ME 04210 Phone: 207-795-8475 Fax: 207-795-8490 |